<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Voyager Therapeutics, Inc. — News on 6ix</title>
<link>https://6ix.com/company/voyager-therapeutics-inc</link>
<description>Latest news and press releases for Voyager Therapeutics, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:31:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/voyager-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d59178dffbe2df121715.webp</url>
<title>Voyager Therapeutics, Inc.</title>
<link>https://6ix.com/company/voyager-therapeutics-inc</link>
</image>
<item>
<title>Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-iv-delivered-cns-gene-therapies-featured-in-multiple-presentations-at-asgct-2026-including-late-breaker-on-tau-targeted-vy1706-for-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-iv-delivered-cns-gene-therapies-featured-in-multiple-presentations-at-asgct-2026-including-late-breaker-on-tau-targeted-vy1706-for-alzheimers-disease</guid>
<pubDate>Mon, 27 Apr 2026 20:31:00 GMT</pubDate>
<description>- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology study in NHPs - - Additional data demonstrate continued capsid innovation via muscular and neuromuscular targeting, immune evasion, and manufacturability - LEXINGTON, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurolo</description>
</item>
<item>
<title>Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-fourth-quarter-and-full-year-2025-financial-and-operating-results</guid>
<pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
<description>- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 - - Validating brain-targeted capsids in humans:</description>
</item>
<item>
<title>Voyager to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-present-upcoming-investor-conferences-130000121</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-present-upcoming-investor-conferences-130000121</guid>
<pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026: Fireside chat at 1:00 p.m. ET on Wednesday, February 11, 2026, in New York, NY.Oppenheimer 36th Annual Healthcare Life Sciences Conference: Fireside chat at 3:20 p.m. E</description>
</item>
<item>
<title>Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/transition-bio-voyager-announce-collaboration-130100600</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/transition-bio-voyager-announce-collaboration-130100600</guid>
<pubDate>Mon, 10 Nov 2025 13:01:00 GMT</pubDate>
<description>CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates, and Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, have entered into a drug discovery collaboration and license option agreement. The companies will collaborate to discover and develop novel, selective</description>
</item>
<item>
<title>Voyager Reports Third Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-third-quarter-2025-130100822</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-third-quarter-2025-130100822</guid>
<pubDate>Mon, 10 Nov 2025 13:01:00 GMT</pubDate>
<description>- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small molecule collaboration - - Ended 3Q25 with cash position of $229 million, maintaining runway into 2028 - LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases,</description>
</item>
<item>
<title>Voyager Reports Second Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-second-quarter-2025-200100369</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-second-quarter-2025-200100369</guid>
<pubDate>Wed, 06 Aug 2025 20:01:00 GMT</pubDate>
<description>- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs - - APOE program added to pipeline; fourth asset in industry-leading Alzheimer’s disease franchise - - 11 partnered programs with potential for $2.6B in development-stage milestone payments - LEXINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today reported second quart</description>
</item>
<item>
<title>Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-adds-fourth-wholly-owned-110000147</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-adds-fourth-wholly-owned-110000147</guid>
<pubDate>Wed, 16 Jul 2025 11:00:00 GMT</pubDate>
<description>- New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager’s wholly-owned Alzheimer’s disease franchise now includes clinical-stage anti-tau antibody VY7523 as well as gene therapies targeting tau, amyloid, and APOE - LEXINGTON, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging gene</description>
</item>
<item>
<title>Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-present-h-c-wainwright-110000385</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-present-h-c-wainwright-110000385</guid>
<pubDate>Tue, 10 Jun 2025 11:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be avail</description>
</item>
<item>
<title>Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-demonstrates-alpl-receptor-mediated-110000295</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-demonstrates-alpl-receptor-mediated-110000295</guid>
<pubDate>Thu, 15 May 2025 11:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced the first peer-reviewed publication of data demonstrating the ability of alkaline phosphatase (ALPL) to transport a novel AAV capsid across the blood-brain barrier (BBB). The article, titled “Highly conserved brain vascular receptor ALPL mediates transport of engineered AAV vectors across the blood-b</description>
</item>
<item>
<title>Voyager Reports First Quarter 2025 Financial and Operating Results</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-first-quarter-2025-200100207</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-first-quarter-2025-200100207</guid>
<pubDate>Tue, 06 May 2025 20:01:00 GMT</pubDate>
<description>– Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg – – Recent Voyager data on VY7523 and VY1706 presented at AD/PD™ 2025 continue to support tau as next critical target in Alzheimer’s disease – LEXINGTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurol</description>
</item>
<item>
<title>Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-next-generation-cns-capsids-203000971</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-next-generation-cns-capsids-203000971</guid>
<pubDate>Mon, 28 Apr 2025 20:30:00 GMT</pubDate>
<description>- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg - - Featured data also include anti-amyloid gene therapy for Alzheimer’s disease, as well as multiple presentations on Voyager’s continued enhancements to its highly BBB penetrant novel capsids - LEXINGTON, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedic</description>
</item>
<item>
<title>Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-presents-robust-preclinical-data-110000950</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-presents-robust-preclinical-data-110000950</guid>
<pubDate>Mon, 31 Mar 2025 11:00:00 GMT</pubDate>
<description>- Single IV administration of tau silencing gene therapy VY1706 significantly reduced tau mRNA and protein levels, with broad brain distribution and liver de-targeting, in NHP study - - Preclinical murine data strengthen case for specifically targeting pathologic forms of tau with the clinical-stage anti-tau antibody VY7523 - - Voyager to host live webcast on April 7 recapping key AD/PD™ 2025 data - LEXINGTON, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a</description>
</item>
<item>
<title>Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-fourth-quarter-full-200100057</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-fourth-quarter-full-200100057</guid>
<pubDate>Tue, 11 Mar 2025 20:01:00 GMT</pubDate>
<description>- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 - - Anti-tau antibody VY7523 was well tolerated in healthy volunteers and showed dose-proportional pharmacokinetics; initial tau PET imaging data in Alzheimer’s patients expected H2 2026 - LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging gene</description>
</item>
<item>
<title>Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-therapeutics-announces-fourth-quarter-120000456</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-therapeutics-announces-fourth-quarter-120000456</guid>
<pubDate>Tue, 04 Mar 2025 12:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report fourth quarter 2024 financial and operating results after market close on Tuesday, March 11, 2025. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET. A live webcast of the call will be available on the Investors section of the Voyager website at ir.voyagertherapeutics.c</description>
</item>
<item>
<title>Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-positive-topline-data-120000803</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-positive-topline-data-120000803</guid>
<pubDate>Mon, 03 Mar 2025 12:00:00 GMT</pubDate>
<description>- Topline SAD data from healthy volunteers demonstrate safety, tolerability, and dose-proportional pharmacokinetics, supporting potentially best-in-class profile - - MAD study initiated in patients with early Alzheimer’s disease; initial tau PET imaging data expected in H2 2026 - LEXINGTON, Mass., March 03, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced positive topline data from the Compa</description>
</item>
<item>
<title>Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-therapeutics-present-multiple-upcoming-120000028</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-therapeutics-present-multiple-upcoming-120000028</guid>
<pubDate>Tue, 25 Feb 2025 12:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the Company will participate in multiple upcoming investor conferences: TD Cowen 45th Annual Health Care Conference, in Boston, including a fireside chat at 1:50 p.m. ET on March 3, 2025Stifel 2025 Virtual CNS Forum, including a fireside chat at 11:00 a.m. ET on March 19, 2025 Webcasts of the presentations will</description>
</item>
<item>
<title>Voyager Provides Update on SOD1 ALS Gene Therapy Program</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-provides-update-on-sod1-als-gene-therapy-program</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-provides-update-on-sod1-als-gene-therapy-program</guid>
<pubDate>Tue, 11 Feb 2025 05:00:00 GMT</pubDate>
<description>- Company to assess alternate payloads; no changes planned to novel capsid component - - Resulting shift of timeline and costs extends cash runway into</description>
</item>
<item>
<title>Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-selects-tau-silencing-gene-therapy-development-candidate-for-alzheimers-disease</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-selects-tau-silencing-gene-therapy-development-candidate-for-alzheimers-disease</guid>
<pubDate>Wed, 20 Nov 2024 05:00:00 GMT</pubDate>
<description>- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in 2026 - - VY1706 is the fifth neuro</description>
</item>
<item>
<title>Voyager Reports Third Quarter 2024 Financial and Operating Results</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-third-quarter-2024-financial-and-operating-results</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-reports-third-quarter-2024-financial-and-operating-results</guid>
<pubDate>Tue, 12 Nov 2024 05:00:00 GMT</pubDate>
<description>- Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1</description>
</item>
<item>
<title>Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast</title>
<link>https://6ix.com/company/voyager-therapeutics-inc/news/voyager-therapeutics-announces-third-quarter-2024-conference-call-and-webcast</link>
<guid isPermaLink="true">https://6ix.com/company/voyager-therapeutics-inc/news/voyager-therapeutics-announces-third-quarter-2024-conference-call-and-webcast</guid>
<pubDate>Tue, 05 Nov 2024 05:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic</description>
</item>
</channel>
</rss>